Estrella Immunopharma Ownership
| ESLA Stock | 0.99 0.04 3.88% |
Estrella |
Estrella Stock Ownership Analysis
About 72.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.24. Estrella Immunopharma had not issued any dividends in recent years. To learn more about Estrella Immunopharma call Cheng Liu at 510 318 9098 or check out https://www.estrellabio.com.Besides selling stocks to institutional investors, Estrella Immunopharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Estrella Immunopharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Estrella Immunopharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Estrella Immunopharma Quarterly Liabilities And Stockholders Equity |
|
About 72.0% of Estrella Immunopharma are currently held by insiders. Unlike Estrella Immunopharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Estrella Immunopharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Estrella Immunopharma's insider trades
Estrella Immunopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Estrella Immunopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Estrella Immunopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Estrella Immunopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jiang Tao over two weeks ago Insider Trading | ||
Zhang Hong over three months ago Discretionary transaction by Zhang Hong of tradable shares of Estrella Immunopharma subject to Rule 16b-3 | ||
Eureka Therapeutics, Inc. over three months ago Disposition of tradable shares by Eureka Therapeutics, Inc. of Estrella Immunopharma subject to Rule 16b-3 | ||
Wu Fan over six months ago Insider Trading | ||
Li Jianwei over six months ago Acquisition by Li Jianwei of 141970 shares of Estrella Immunopharma at 314700.0 subject to Rule 16b-3 | ||
Eureka Therapeutics Inc over a year ago Estrella Immunopharma exotic insider transaction detected |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Estrella Immunopharma is a strong investment it is important to analyze Estrella Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Estrella Immunopharma's future performance. For an informed investment choice regarding Estrella Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Estrella Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Estrella Stock refer to our How to Trade Estrella Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estrella Immunopharma. If investors know Estrella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Estrella Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Estrella Immunopharma is measured differently than its book value, which is the value of Estrella that is recorded on the company's balance sheet. Investors also form their own opinion of Estrella Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Estrella Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estrella Immunopharma's market value can be influenced by many factors that don't directly affect Estrella Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Estrella Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Estrella Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Estrella Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.